Identification

Name
Pyridoxine
Accession Number
DB00165  (NUTR00002, APRD00204)
Type
Small Molecule
Groups
Approved, Nutraceutical, Vet Approved
Description

Pyridoxine is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body. Pyridoxal 5-phosphate is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. Although pyridoxine and vitamin B6 are still frequently used as synonyms, especially by medical researchers, this practice is erroneous and sometimes misleading. [PubChem]

Structure
Thumb
Synonyms
  • 2-Methyl-3-hydroxy-4,5-dihydroxymethylpyridine
  • 3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine
  • 3-Hydroxy-4,5-dimethylol-alpha-picoline
  • 5-Hydroxy-6-methyl-3,4-pyridinedimethanol
  • Pyridoxine
  • Pyridoxol
  • Vitamin B6
Product Ingredients
IngredientUNIICASInChI Key
Pyridoxine hydrochloride68Y4CF58BV58-56-0ZUFQODAHGAHPFQ-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cataplex F Tab 2mgTablet2 mgOralStandard Process Inc.Not applicableNot applicableCanada
Pyridoxine HCl Inj 100mg/mlLiquid100 mgIntramuscular; IntravenousKripps Pharmacy Ltd.1979-12-31Not applicableCanada
Pyridoxine Hydrochloride Injection 100mg/mlSolution100 mgIntramuscular; IntravenousHospira, Inc.1981-12-31Not applicableCanada
Pyridoxine Hydrochloride Injection USP 100 mg/mlSolution100 mgIntramuscular; IntravenousAlveda Pharmaceuticals IncNot applicableNot applicableCanada
Pyridoxine Hydrochloride Injection, USPSolution100 mgIntramuscular; IntravenousMylan Pharmaceuticals2002-06-01Not applicableCanada
Vitamin B6 250 Mg CapsulesCapsule250 mgOralSelf Health Resource CentreNot applicableNot applicableCanada
Vitamin B6 TabletTablet100 mgOralLeiner Health ProductsNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pyridoxine HydrochlorideInjection, solution100 mg/mLIntramuscular; IntravenousFresenius Kabi1972-08-14Not applicableUs
Pyridoxine HydrochlorideInjection, solution100 mg/mLIntramuscular; IntravenousMylan Institutional2016-09-01Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
B-6 500mg Continuous ReleasedTablet, extended release500 mgOralGahler Enterprises Ltd.1981-12-312007-08-07Canada
B-6 Caps 250mgCapsule250 mgOralTwin Laboratories Inc.1995-12-311999-11-10Canada
B6 100mg Pyridoxine HClTablet100 mgOralWn Pharmaceuticals Ltd.2001-10-012009-09-28Canada
B6 25 Tab 25mgTablet25 mgOralLe Naturiste J.M.B. Inc.1990-12-311997-07-23Canada
B6 250 Caplet 250mgTablet250 mgOralHealth Wise Nutrition Inc.1996-11-131997-08-07Canada
B6 400mg Ctr TabTablet, extended release400 mgOralBioenergy Inc.1979-12-311998-06-03Canada
B6 Cap 100mgCapsule100 mgOralGahler Enterprises Ltd.1989-12-312008-07-17Canada
B6 Pyridoxine HCl Tab 50mgTablet50 mgOralGahler Enterprises Ltd.1984-12-312008-07-17Canada
B6 Tab 100mgTablet100 mgOralAlbi Naturals1979-12-312008-07-17Canada
B6 Tablets 100mgTablet100 mgOralGahler Enterprises Ltd.1988-12-312008-07-17Canada
International/Other Brands
Becilan / Beesix / Benadon / Bonasanit / Hexa-Betalin / Hexobion / Nestrex
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
A.R.T.H. Away FormulaPyridoxine hydrochloride (0.5 mg) + Calcium (24 mg) + Cholecalciferol (45 unit) + Copper (0.232 mg) + Folic Acid (0.025 mg) + Manganese (0.58 mg) + Selenium (1.54 mcg) + Zinc (0.63 mg)CapsuleOralAbundance Marketing Ltd.1999-02-012006-06-16Canada
Acetabolan III Vitamin and Mineral SupplementPyridoxine hydrochloride (2.63 mg) + Magnesium (112.5 mg) + Vitamin C (250.0 mg) + Zinc (7.5 mg)CapsuleOralIovate Health Sciences International Inc.2003-12-052007-07-18Canada
Acetabolan-II Vitamin and Mineral SupplementPyridoxine hydrochloride (2.1 mg) + Magnesium (90 mg) + Vitamin C (200 mg) + Zinc (6 mg)CapsuleOralIovate Health Sciences International Inc.2000-11-202005-06-21Canada
Active FEPyridoxine hydrochloride (20 mg/1) + Beta carotene (2100 [iU]/1) + Cholecalciferol (400 [iU]/1) + Cupric oxide (1 mg/1) + Cyanocobalamin (30 ug/1) + Folic Acid (1250 ug/1) + Iron (75 mg/1) + Magnesium oxide (30 mg/1) + Nicotinamide (20 mg/1) + Riboflavin (4 mg/1) + Thiamine Hydrochloride (4 mg/1) + Vitamin C (160 mg/1) + Vitamin E (40 [iU]/1) + Zinc oxide (20 mg/1)TabletOralGm Pharmaceuticals2013-11-11Not applicableUs
AcvPyridoxine hydrochloride (5 mg) + Chromium (150 mcg)TabletOralAbundance Marketing Ltd.2001-10-012004-06-30Canada
Adrenogist TabPyridoxine hydrochloride (5 mg) + Pantothenic acid (100 mg) + Potassium Chloride (99 mg)TabletOralPure Life International Prods Inc.1992-12-312000-07-27Canada
Adult Infuvite Multiple VitaminsPyridoxine hydrochloride (6 mg/10mL) + Biotin (60 ug/10mL) + Cholecalciferol (200 [iU]/10mL) + Cyanocobalamin (5 ug/10mL) + Dexpanthenol (15 mg/10mL) + Folic Acid (600 ug/10mL) + Nicotinamide (40 mg/10mL) + Phylloquinone (150 ug/10mL) + Riboflavin 5'-phosphate sodium (3.6 mg/10mL) + Thiamine Hydrochloride (6 mg/10mL) + Vitamin A palmitate (3300 [iU]/10mL) + Vitamin C (200 mg/10mL) + Vitamin E acetate (10 [iU]/10mL)Injection, solutionIntravenousSandoz2005-05-18Not applicableUs
Adult Infuvite Multiple VitaminsPyridoxine hydrochloride (6 mg/10mL) + Biotin (60 ug/10mL) + Cholecalciferol (200 [iU]/10mL) + Cyanocobalamin (5 ug/10mL) + Dexpanthenol (15 mg/10mL) + Folic Acid (600 ug/10mL) + Nicotinamide (40 mg/10mL) + Phylloquinone (150 ug/10mL) + Riboflavin 5'-phosphate sodium (3.6 mg/10mL) + Thiamine Hydrochloride (6 mg/10mL) + Vitamin A palmitate (3300 [iU]/10mL) + Vitamin C (200 mg/10mL) + Vitamin E acetate (10 [iU]/10mL)Injection, solutionIntravenousSandoz2003-06-16Not applicableUs
Adult Infuvite Multiple VitaminsPyridoxine hydrochloride (6 mg/10mL) + Biotin (60 ug/10mL) + Cholecalciferol (200 [iU]/10mL) + Cyanocobalamin (5 ug/10mL) + Dexpanthenol (15 mg/10mL) + Folic Acid (600 ug/10mL) + Nicotinamide (40 mg/10mL) + Phylloquinone (150 ug/10mL) + Riboflavin 5'-phosphate sodium (3.6 mg/10mL) + Thiamine Hydrochloride (6 mg/10mL) + Vitamin A palmitate (3300 [iU]/10mL) + Vitamin C (200 mg/10mL) + Vitamin E acetate (10 [iU]/10mL)Injection, solutionIntravenousSandoz2003-06-16Not applicableUs
Adult Infuvite Multiple VitaminsPyridoxine hydrochloride (6 mg/10mL) + Biotin (60 ug/10mL) + Cholecalciferol (200 [iU]/10mL) + Cyanocobalamin (5 ug/10mL) + Dexpanthenol (15 mg/10mL) + Folic Acid (600 ug/10mL) + Nicotinamide (40 mg/10mL) + Phylloquinone (150 ug/10mL) + Riboflavin 5'-phosphate sodium (3.6 mg/10mL) + Thiamine Hydrochloride (6 mg/10mL) + Vitamin A palmitate (3300 [iU]/10mL) + Vitamin C (200 mg/10mL) + Vitamin E acetate (10 [iU]/10mL)Injection, solutionIntravenousSandoz2005-05-18Not applicableUs
Categories
UNII
KV2JZ1BI6Z
CAS number
65-23-6
Weight
Average: 169.1778
Monoisotopic: 169.073893223
Chemical Formula
C8H11NO3
InChI Key
LXNHXLLTXMVWPM-UHFFFAOYSA-N
InChI
InChI=1S/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H3
IUPAC Name
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol
SMILES
CC1=C(O)C(CO)=C(CO)C=N1

Pharmacology

Indication

For the treatment of vitamin B6 deficiency and for the prophylaxis of isoniazid-induced peripheral neuropathy.

Structured Indications
Not Available
Pharmacodynamics

Vitamin B6 (pyridoxine) is a water-soluble vitamin used in the prophylaxis and treatment of vitamin B6 deficiency and peripheral neuropathy in those receiving isoniazid (isonicotinic acid hydrazide, INH). Vitamin B6 has been found to lower systolic and diastolic blood pressure in a small group of subjects with essential hypertension. Hypertension is another risk factor for atherosclerosis and coronary heart disease. Another study showed pyridoxine hydrochloride to inhibit ADP- or epinephrine-induced platelet aggregation and to lower total cholesterol levels and increase HDL-cholesterol levels, again in a small group of subjects. Vitamin B6, in the form of pyridoxal 5'-phosphate, was found to protect vascular endothelial cells in culture from injury by activated platelets. Endothelial injury and dysfunction are critical initiating events in the pathogenesis of atherosclerosis. Human studies have demonstrated that vitamin B6 deficiency affects cellular and humoral responses of the immune system. Vitamin B6 deficiency results in altered lymphocyte differentiation and maturation, reduced delayed-type hypersensitivity (DTH) responses, impaired antibody production, decreased lymphocyte proliferation and decreased interleukin (IL)-2 production, among other immunologic activities.

Mechanism of action

Vitamin B6 is the collective term for a group of three related compounds, pyridoxine (PN), pyridoxal (PL) and pyridoxamine (PM), and their phosphorylated derivatives, pyridoxine 5'-phosphate (PNP), pyridoxal 5'-phosphate (PLP) and pyridoxamine 5'-phosphate (PMP). Although all six of these compounds should technically be referred to as vitamin B6, the term vitamin B6 is commonly used interchangeably with just one of them, pyridoxine. Vitamin B6, principally in its biologically active coenzyme form pyridoxal 5'-phosphate, is involved in a wide range of biochemical reactions, including the metabolism of amino acids and glycogen, the synthesis of nucleic acids, hemogloblin, sphingomyelin and other sphingolipids, and the synthesis of the neurotransmitters serotonin, dopamine, norepinephrine and gamma-aminobutyric acid (GABA).

TargetActionsOrganism
APyridoxal kinase
ligand
Human
Absorption

The B vitamins are readily absorbed from the gastrointestinal tract, except in malabsorption syndromes. Pyridoxine is absorbed mainly in the jejunum.

Volume of distribution
Not Available
Protein binding

22%

Metabolism

Hepatic.

Route of elimination
Not Available
Half life

15-20 days

Clearance
Not Available
Toxicity

Oral Rat LD50 = 4 gm/kg. Toxic effects include convulsions, dyspnea, hypermotility, diarrhea, ataxia and muscle weakness.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
HypophosphatasiaDisease
Vitamin B6 MetabolismMetabolic
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AltretamineThe therapeutic efficacy of Altretamine can be decreased when used in combination with Pyridoxine.Approved
AmobarbitalThe metabolism of Amobarbital can be increased when combined with Pyridoxine.Approved, Illicit
BarbexacloneThe metabolism of Barbexaclone can be increased when combined with Pyridoxine.Experimental
BarbitalThe metabolism of Barbital can be increased when combined with Pyridoxine.Illicit
FosphenytoinThe metabolism of Fosphenytoin can be increased when combined with Pyridoxine.Approved
HexobarbitalThe metabolism of Hexobarbital can be increased when combined with Pyridoxine.Approved
LevodopaThe therapeutic efficacy of Levodopa can be decreased when used in combination with Pyridoxine.Approved
MethohexitalThe metabolism of Methohexital can be increased when combined with Pyridoxine.Approved
MethylphenobarbitalThe metabolism of Methylphenobarbital can be increased when combined with Pyridoxine.Approved
PentobarbitalThe metabolism of Pentobarbital can be increased when combined with Pyridoxine.Approved, Vet Approved
PhenobarbitalThe metabolism of Phenobarbital can be increased when combined with Pyridoxine.Approved
PhenytoinThe metabolism of Phenytoin can be increased when combined with Pyridoxine.Approved, Vet Approved
PrimidoneThe metabolism of Primidone can be increased when combined with Pyridoxine.Approved, Vet Approved
SecobarbitalThe metabolism of Secobarbital can be increased when combined with Pyridoxine.Approved, Vet Approved
ThiamylalThe metabolism of Thiamylal can be increased when combined with Pyridoxine.Approved, Vet Approved
ThiopentalThe metabolism of Thiopental can be increased when combined with Pyridoxine.Approved, Vet Approved
Food Interactions
Not Available

References

Synthesis Reference

Harumi Kita, "Production of pyridoxine." U.S. Patent US4339586, issued October, 1972.

US4339586
General References
Not Available
External Links
Human Metabolome Database
HMDB00239
KEGG Compound
C00314
PubChem Compound
1054
PubChem Substance
46508560
ChemSpider
1025
BindingDB
50103505
ChEBI
16709
ChEMBL
CHEMBL1364
Therapeutic Targets Database
DAP000869
PharmGKB
PA451897
HET
UEG
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Pyridoxine
ATC Codes
A11HA02 — Pyridoxine (vit b6)
AHFS Codes
  • 88:08.00 — Vitamin B Complex
PDB Entries
4c5l / 4c5n / 5eb3
MSDS
Download (51.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections / Infection, Human Immunodeficiency Virus I / Mycobacterium avium complex infection1
1CompletedDiagnosticHealthy Volunteers1
1CompletedOtherHeart Rate / Heart Rate Variability / Inflammatory Reaction1
1CompletedPreventionHIV / AIDS1
1CompletedTreatmentCancers / Metastases1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
1Not Yet RecruitingBasic ScienceAging / Mineral deficiency / Vitamin Deficiency1
1, 2Active Not RecruitingTreatmentAdvanced Cancers / Malignant Lymphomas1
1, 2Not Yet RecruitingTreatmentMalignant Lymphomas / Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic1
1, 2RecruitingTreatmentMalignant Lymphomas1
1, 2SuspendedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
1, 2TerminatedTreatmentPsoriasis1
1, 2WithdrawnTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
2CompletedPreventionHerpes simplex of the genitals / Ulcers1
2CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentEpilepsies / Infantile Spasms (IS)1
2RecruitingPreventionVincristine Induced Peripheral Neuropathy (VIPN)1
2RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
2RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2RecruitingTreatmentMultiple Myeloma (MM)1
2Unknown StatusTreatmentNodding Syndrome1
2WithdrawnTreatmentColorectal Cancers1
2WithdrawnTreatmentMalignant Lymphomas1
2WithdrawnTreatmentPlasma Cell Myeloma1
2, 3CompletedTreatmentAtherosclerosis1
2, 3CompletedTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Mortality1
3CompletedPreventionCerebral Infarctions / Myocardial Infarction (MI) / Strokes1
3CompletedPreventionCerebrovascular Stroke / Coronary Artery Disease / Myocardial Infarction (MI)1
3CompletedPreventionComplications, Pregnancy / Human Immunodeficiency Virus (HIV) Infections1
3CompletedPreventionHand-foot Syndrome1
3CompletedPreventionHyperemesis Gravidarum / Pregnancy1
3CompletedSupportive CareCancer Related Fatigue / Quality of Life1
3CompletedTreatmentAlzheimer's Disease (AD)1
3CompletedTreatmentAnemias1
3CompletedTreatmentDiarrheal Illnesses / Growth Faltering / Respiratory Illness1
3CompletedTreatmentEndometrial Biopsy1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis, Pulmonary1
3CompletedTreatmentHydatidiform Mole1
3CompletedTreatmentNausea and Vomiting of Pregnancy1
3Unknown StatusNot AvailableAnemias / Low Birth Weight / Neonatal Mortality1
3Unknown StatusTreatmentAlzheimer's Disease (AD) / Down Syndrome (DS)1
3WithdrawnPreventionTardive Dyskinesia1
4CompletedTreatmentAcute Schizophrenia1
4CompletedTreatmentDiabetic Peripheral Neuropathic Pain1
4CompletedTreatmentHyperemesis Gravidarum / Morning Sickness / Nausea / Pregnancy / Vomiting1
4CompletedTreatmentPregnancy1
4RecruitingOtherAlcohol Abuse / HIV / AIDS / Tuberculosis1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4RecruitingTreatmentLeiomyomas1
4RecruitingTreatmentMorning Sickness1
4Unknown StatusTreatmentNausea and Vomiting Complain in Early Pregnancy1
4WithdrawnTreatmentNephritis / Proteinuria / Systemic Lupus Erythematosus (SLE)1
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
Not AvailableCompletedPreventionNeural Tube Defects (NTDs)1
Not AvailableCompletedTreatmentAcute Myocardial Infarction (AMI)1
Not AvailableCompletedTreatmentEnd Stage Renal Disease (ESRD) / Hyperhomocysteinaemia1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis4
Not AvailableNot Yet RecruitingTreatmentBreast Cancer Metastatic / Metastatic Breast Cancer (MBC)1
Not AvailableRecruitingTreatmentTemporomandibular Joint Disorders1
Not AvailableUnknown StatusPreventionHand and foot syndrome secondary to sickle cell anaemia1
Not AvailableUnknown StatusTreatmentAbnormal Uterine Bleeding Unrelated to Menstrual Cycle1
Not AvailableWithdrawnNot AvailablePyridoxine Dependant Epilepsy1
Not AvailableWithdrawnPreventionStrokes / Transient Ischaemic Attack (TIA)1

Pharmacoeconomics

Manufacturers
  • Eli lilly and co
  • Akorn inc
  • App pharmaceuticals llc
  • Bel mar laboratories inc
  • Dell laboratories inc
  • Elkins sinn div ah robins co inc
  • Luitpold pharmaceuticals inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Capsule; liquidOral
ElixirOral
Tablet, extended releaseOral
Tablet, extended releaseOral500 mg
InjectionIntramuscular
Injection, solutionIntramuscular; Intravenous
Tablet, extended releaseOral400 mg
Powder, for solutionIntramuscular; Intravenous
Powder, for solutionIntravenous
WaferOral
TabletOral2 mg
CreamTopical
Kit
TabletOral
SprayTopical
Tablet, delayed releaseOral
SyrupOral
TabletOral8.45 mg
LiquidIntramuscular; Intravenous
PowderOral
Tablet, chewableOral
TabletOral6 mg
TabletOral8.33 mg
TabletOral10 mg
LiquidIntravenous
Injection, powder, lyophilized, for solutionIntravenous
Liquid; tabletOral
Solution / dropsOral
SolutionIntravenous
LiquidOral
SolutionOral
Capsule, gelatin coatedOral
SolutionIntramuscular; Intravenous
CapsuleOral
Injection, solutionIntravenous
PasteDental
Tablet, coatedOral
LiquidIntramuscular; Intravenous100 mg
Injection, solutionIntramuscular; Intravenous100 mg/mL
SolutionIntramuscular; Intravenous100 mg
Tablet, effervescentOral
Powder, for solutionOral
KitOral
Capsule, extended releaseOral
Tablet, extended releaseOral100 mg
TabletOral50 mg
CapsuleOral250 mg
Capsule, liquid filledOral
InjectionIntramuscular; Intravenous
InjectionIntravenous
CapsuleOral100 mg
TabletOral17 mg
CapsuleOral200 mg
TabletOral200 mg
CapsuleOral3.5 mg
TabletOral250 mg
TabletOral100 mg
TabletOral25 mg
Tablet, film coatedOral
LozengeOral
Prices
Unit descriptionCostUnit
Pyridoxine HCl 100 50 mg tablet Bottle12.99USD bottle
Pyridoxine HCl 100 mg/ml vial11.69USD vial
Pyridoxine 100 mg/ml vial10.79USD ml
Pyridoxine hcl crystals6.94USD g
Pyridoxine 500 mg tablet0.18USD tablet
Pyridoxine 25 mg tablet0.14USD tablet
Neuro k 500 mg tablet0.13USD tablet
Pyridoxine 250 mg tablet0.13USD tablet
CVS Pharmacy vitamin b-6 200 mg tablet0.07USD tablet
Neuro-k 250 mg tablet0.06USD tablet
Pyridoxine 50 mg tablet0.06USD tablet
Vitamin b-6 100 mg tablet0.04USD tablet
CVS Pharmacy vitamin b-6 100 mg tablet0.03USD tablet
Pyridoxine 100 mg tablet0.03USD tablet
Vitamin b6 50 mg tablet0.03USD tablet
Vitamin b-6 50 mg tablet0.03USD tablet
CVS Pharmacy vitamin b-6 50 mg tablet0.02USD tablet
Vitamin b-6 25 mg tablet0.02USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6340695No2001-06-212021-06-21Us
US7560122No1999-01-252019-01-25Us
US9526703No2013-02-182033-02-18Us
US9375404No2013-02-182033-02-18Us
US9089489No2013-02-182033-02-18Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)159-162 °CPhysProp
water solubility2.2E+005 mg/LNot Available
logP-0.77SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility16.1 mg/mLALOGPS
logP-0.57ALOGPS
logP-0.95ChemAxon
logS-1ALOGPS
pKa (Strongest Acidic)9.4ChemAxon
pKa (Strongest Basic)5.58ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area73.58 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity44.11 m3·mol-1ChemAxon
Polarizability17.11 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9728
Blood Brain Barrier+0.6889
Caco-2 permeable-0.8958
P-glycoprotein substrateNon-substrate0.5579
P-glycoprotein inhibitor INon-inhibitor0.9723
P-glycoprotein inhibitor IINon-inhibitor0.9221
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.7386
CYP450 2D6 substrateNon-substrate0.781
CYP450 3A4 substrateNon-substrate0.7104
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8648
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.695
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9418
BiodegradationNot ready biodegradable0.5678
Rat acute toxicity1.6573 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8454
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)GC-MSsplash10-000t-0940000000-30b4702623a6d8fcb4bb
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-001j-0690000000-0581e2b42fa48c1ea498
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)GC-MSsplash10-00di-9330000000-32929ff06762b9f5887f
GC-MS Spectrum - GC-MS (3 TMS)GC-MSsplash10-001i-0490000000-34a09ddbbb462aeb02a6
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0f6x-9400000000-486db54a30b61c2eb9d4
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-000t-0940000000-30b4702623a6d8fcb4bb
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-001j-0690000000-0581e2b42fa48c1ea498
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00di-9330000000-32929ff06762b9f5887f
GC-MS Spectrum - GC-MSGC-MSsplash10-001i-0490000000-34a09ddbbb462aeb02a6
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-001j-0790000000-6f8f6e679e03f9119a65
Mass Spectrum (Electron Ionization)MSsplash10-1003-6900000000-1237eaf82dfadfd54d4b
MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)LC-MS/MSsplash10-0vi0-0900000000-bd0de86c072765a5caad
MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)LC-MS/MSsplash10-001i-3900000000-2018b406a3c75213b733
MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)LC-MS/MSsplash10-0059-9200000000-e69bb531deb2a103a476
MS/MS Spectrum - EI-B (HITACHI M-80) , PositiveLC-MS/MSsplash10-0f6x-9400000000-77c43a946c4ae1abf3b9
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, NegativeLC-MS/MSsplash10-014i-0900000000-479d4492cc8d634fa366
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, NegativeLC-MS/MSsplash10-0udi-0900000000-486d6a4e5e1a731b7c54
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, NegativeLC-MS/MSsplash10-05fr-0900000000-4ef09ce9c04561a1085e
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, NegativeLC-MS/MSsplash10-0ab9-1900000000-3298adf6db36689d5d43
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, NegativeLC-MS/MSsplash10-0a6r-7900000000-6711954ee96f08344434
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, PositiveLC-MS/MSsplash10-00di-0900000000-234e90d43a7febd7a098
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, PositiveLC-MS/MSsplash10-0udi-0900000000-137080765c0035b45258
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, PositiveLC-MS/MSsplash10-001i-0900000000-882ee900a8bba08e2c7c
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, PositiveLC-MS/MSsplash10-003r-8900000000-e0e11797b63cea991d81
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, PositiveLC-MS/MSsplash10-0059-9100000000-c25384179219411af02c
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , PositiveLC-MS/MSsplash10-0ue9-0900000000-c0e149ce890192397b7f
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , NegativeLC-MS/MSsplash10-0v4i-0900000000-f9f378af3d47ab006806
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0uk9-0900000000-eab5b3411261744df750
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0ue9-0900000000-cc4dc8719602182ef1eb
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-5900000000-1c2637733578fcdd7c6a
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0900000000-e89cc69d8b21012ff982
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-059i-0900000000-0ad8d09e042015cb2e33
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9500000000-577a3d87899ca47d539f
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-0900000000-479d4492cc8d634fa366
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0udi-0900000000-486d6a4e5e1a731b7c54
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-05fr-0900000000-4ef09ce9c04561a1085e
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0ab9-1900000000-3298adf6db36689d5d43
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0a6r-7900000000-6711954ee96f08344434
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0v4i-0900000000-f9f378af3d47ab006806
MS/MS Spectrum - , negativeLC-MS/MSsplash10-0uxr-0900000000-dd61975d762fdc6e1e95
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-0900000000-234e90d43a7febd7a098
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udi-0900000000-137080765c0035b45258
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0900000000-882ee900a8bba08e2c7c
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-003r-8900000000-ffea92733494372f905d
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0059-9100000000-ef6ae8502e892d6053f0
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0ue9-0900000000-c0e149ce890192397b7f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0900000000-99bef4a72e90ec8f7ea6
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,1H] 2D NMR Spectrum2D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyridoxines. These are pyridoxal derivatives in which the carbaldehyde group at position 2 of the pyridoxal moiety is replaced by a hydroxymethyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Pyridoxines
Direct Parent
Pyridoxines
Alternative Parents
Methylpyridines / Hydroxypyridines / Heteroaromatic compounds / Azacyclic compounds / Primary alcohols / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives / Aromatic alcohols
Substituents
Pyridoxine / Methylpyridine / Hydroxypyridine / Heteroaromatic compound / Azacycle / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative / Aromatic alcohol
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
monohydroxypyridine, methylpyridines, vitamin B6, hydroxymethylpyridine (CHEBI:16709) / Water-soluble vitamins (C00314) / a vitamin B6 (PYRIDOXINE)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Ligand
General Function
Zinc ion binding
Specific Function
Required for synthesis of pyridoxal-5-phosphate from vitamin B6.
Gene Name
PDXK
Uniprot ID
O00764
Uniprot Name
Pyridoxal kinase
Molecular Weight
35102.105 Da
References
  1. Adams JB, George F, Audhya T: Abnormally high plasma levels of vitamin B6 in children with autism not taking supplements compared to controls not taking supplements. J Altern Complement Med. 2006 Jan-Feb;12(1):59-63. [PubMed:16494569]
  2. Newman JA, Das SK, Sedelnikova SE, Rice DW: The crystal structure of an ADP complex of Bacillus subtilis pyridoxal kinase provides evidence for the parallel emergence of enzyme activity during evolution. J Mol Biol. 2006 Oct 20;363(2):520-30. Epub 2006 Aug 12. [PubMed:16978644]
  3. Kim SY, An JJ, Kim DW, Choi SH, Lee SH, Hwang SI, Kwon OS, Kang TC, Won MH, Cho SW, Park J, Eum WS, Lee KS, Choi SY: Tat-mediated protein transduction of human brain pyridoxine-5-P oxidase into PC12 cells. J Biochem Mol Biol. 2006 Jan 31;39(1):76-83. [PubMed:16466641]
  4. Nagahashi Y, Tazoe M, Hoshino T: Cloning of the pyridoxine 5'-phosphate phosphatase gene (pdxP) and vitamin B6 production in pdxP recombinant Sinorhizobium meliloti. Biosci Biotechnol Biochem. 2008 Feb;72(2):421-7. Epub 2008 Feb 7. [PubMed:18256491]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Tangjarukij C, Navasumrit P, Zelikoff JT, Ruchirawat M: The effects of pyridoxine deficiency and supplementation on hematological profiles, lymphocyte function, and hepatic cytochrome P450 in B6C3F1 mice. J Immunotoxicol. 2009 Sep;6(3):147-60. doi: 10.1080/15476910903083866. [PubMed:19637937]

Drug created on June 13, 2005 07:24 / Updated on October 23, 2017 14:13